Foster Victor Wealth Advisors LLC Sells 4,817 Shares of Amgen Inc. $AMGN

Foster Victor Wealth Advisors LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,878 shares of the medical research company’s stock after selling 4,817 shares during the quarter. Amgen makes up about 1.1% of Foster Victor Wealth Advisors LLC’s portfolio, making the stock its 19th biggest position. Foster Victor Wealth Advisors LLC’s holdings in Amgen were worth $25,445,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of AMGN. Massachusetts Wealth Management lifted its position in shares of Amgen by 6.7% during the third quarter. Massachusetts Wealth Management now owns 6,772 shares of the medical research company’s stock valued at $2,855,000 after buying an additional 425 shares during the last quarter. PFS Partners LLC boosted its holdings in shares of Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after buying an additional 42 shares in the last quarter. White Lighthouse Investment Management Inc. grew its position in shares of Amgen by 3.9% in the 3rd quarter. White Lighthouse Investment Management Inc. now owns 2,735 shares of the medical research company’s stock worth $1,153,000 after buying an additional 102 shares during the last quarter. Trifecta Capital Advisors LLC grew its position in shares of Amgen by 6.1% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 17,513 shares of the medical research company’s stock worth $7,382,000 after buying an additional 1,011 shares during the last quarter. Finally, Crossmark Global Holdings Inc. grew its position in shares of Amgen by 88.7% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 75,992 shares of the medical research company’s stock worth $32,031,000 after buying an additional 35,730 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $438.34 on Thursday. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03. The firm has a market capitalization of $236.98 billion, a price-to-earnings ratio of 27.24, a PEG ratio of 3.21 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock’s 50-day simple moving average is $416.63 and its 200-day simple moving average is $376.69.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire delivered strong Phase 3 results. Amgen and AstraZeneca reported that Tezspire produced statistically significant improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. Reuters reported a 69% remission rate, strengthening the case for a potential expansion of Tezspire beyond asthma. Reuters Tezspire Phase 3 results
• Positive Sentiment: Analysts remain bullish. Piper Sandler maintained a Buy rating and set a $457 price target, while Goldman Sachs raised its target to $481. The revisions indicate continued confidence in Amgen’s pipeline, earnings outlook and portfolio diversification. Piper Sandler Amgen rating
• Positive Sentiment: Recent financial performance supports the growth narrative. Amgen’s latest quarterly results exceeded expectations, with earnings per share of $6.29 versus the $5.62 consensus and revenue of $10.05 billion versus $9.43 billion expected. Revenue increased 9.5% year over year, helping reinforce the investment story. Amgen earnings beat analysis
• Neutral Sentiment: Additional catalysts are approaching. Amgen plans to present oncology data and other research at the European Society for Medical Oncology Congress on October 24, which could provide further pipeline updates. Amgen ESMO 2026 presentation
• Negative Sentiment: Valuation and execution risks remain. Amgen trades at a considerably higher valuation than Bristol Myers Squibb, according to comparative coverage, leaving less room for disappointment. Tezspire’s opportunity also depends on regulatory approval and successful commercialization in EoE. Amgen versus Bristol Myers Squibb comparison

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AMGN shares. Argus increased their target price on shares of Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. Barclays raised their target price on shares of Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday. HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and cut their price target for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. Canaccord Genuity Group upped their price target on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Finally, Guggenheim reduced their price target on Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $388.64.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.